

Press release 2012-01-12

WntResearch: Nils Brünner steps up as new CEO

WntResearch AB (WNT.ST) announces that Nils Brünner accepts the position as the new CEO of WntResearch. The change is established to strengthen the focus on the Clinical Development following the positive tox-studies of Foxy-5 as announced in December 2011. Bert Junno will take the role as Chief Financial Officer (CFO) of the Company and maintains his role as member of the Board. Together this means an improved and broader qualification of the leadership running the Company.

Chairman of the Board Peter Buhl Jensen comments:

I'm very happy that Professor Brünner has accepted the position as a CEO of the Company. Dr. Nils Brünner is a highly respected and world class oncology specialist with an international network which is of huge value to the Company. Brünner serves the advisory role in several biotech and big diagnostic companies and in key organizations in the international oncology community and has many years of successful experience as an innovative leader. Professor Brünner has been scientific advisor to WntResearch since 2008. I look forward to our future collaboration that will focus on the creation of value to the shareholders by optimizing the clinical development of Foxy-5 for the treatment of metastatic cancer and on building partnerships.

I'm grateful to Bert Junno who successfully led WntResearch from a small spin-out company from Lund University to a listed public company on AktieTorget and welcomes Bert in his new position as CFO of WntResearch.

For further information please contact:

Peter Buhl Jensen, Chairman of the Board
E-mail: pbj@buhloncology.com
Telephone: +45 2160 8922

About WntResearch AB

WntResearch (WNT.ST) is a public company listed at the AktieTorget and is a research based Biotech Company spun out of Lund University, Sweden, founded in 2007. The focus and aim of WntResearch is to develop novel anti-metastatic therapies, in areas of unmet need, for the treatment of cancer patients. The company has two major drug development projects, Foxy-5 and Box-5. The lead project Foxy-5 is currently being tested in in-vivo models and is planned to enter phase 1 clinical trials in metastatic cancer in 2012.